NCT02023606View on ClinicalTrials.gov

Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
DRUG

SPN-810M

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT02023606 - Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M | Biotech Hunter | Biotech Hunter